All In Biotech

Drug Trial Radar · NCT07646535

A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary Aldosteronism

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary Aldosteronism

Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Jun 12, 2026

Primary completion

Apr 1, 2027

Study completion Dec 31, 2027

Sponsor

Sponsor type
Industry
First posted
Jun 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled phase II study designed to explore the efficacy and safety of different doses of SAL0140 in primary aldosteronism.

Conditions

  • Primary Aldosteronism

Interventions

  • SAL0140 TabletsDrug

    Drug: SAL0140 Tablets

  • SAL0140 TabletsDrug

    SAL0140 Tablets

  • SAL0140 placeboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The baseline change in mean seated systolic blood pressure (msSBP)Time frame: at week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.